ABSTRACT
Background Several municipalities in the Lombardy Region have been affected by the SARS-CoV-2 infection since the earliest stages of the epidemic. To date, 89442 confirmed cases have been diagnosed in Lombardy, and mortality in several municipalities has already surpassed that of the past decade. Currently, the true extent of the SARS-CoV-2 infection remains unknown as several affected subjects may have been asymptomatic or have presented mild disease, thus not resulting in the identified COVID-19 cases.
Methods This cross-sectional study aims to define the spread of infection within the population by determining the seroprevalence of IgG antibodies directed against SARS-CoV-2 by rapid immunochromatographic testing and subsequent confirmation by serology on venous blood by liquid phase immunochemical testing, also allowing to compare the two methods. Testing will be performed on adults and minors residing, domiciled or working in several municipalities of the Lombardy Region, involved in the initial stages of the epidemic. The study will include rapid finger-prick testing and venous sampling for antibodies against SARS-CoV-2, and nasopharyngeal swabbing (NPS). Concurrent notification of test results will occur via the regional healthcare information system (SISS).
Discussion This study was developed with the desire to understand the seroprevalence of SARS-CoV-2 infection and the epidemiological transmission characteristics of this virus. Understanding the spread and severity of the disease could help in the implementation of effective infection surveillance containment and countermeasures facilitating the identification of cases that have been exposed to the virus and the traceability of contacts.
This study has been approved by the Ethics Committee of the University of Milan (35/2020).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study will be carried out with the non-conditioning contribution of CISOM, Fondazione Rava, Armani C/O Unimi e Mediolanum C/O Fbf/Sacco. Vittore Scolari received support from the LabEx DEEP (ANR-11-LABX-0044, ANR-10-IDEX-0001-02)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Ethics Committee of the University of Milan (35/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The article is reporting the protocol for the study. Data will be available as soon as the study will be completed
LIST OF ABBREVIATIONS
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- COVID-19
- COronaVirus Induced Disease 2019
- rRT-PCR
- real-time reverse transcription polymerase chain reaction
- NPS
- nasopharyngeal swab
- SISS
- Sistema Informativo SocioSanitario (regional healthcare information system)
- WHO
- World Health Organization
- PPE
- personal protective equipment
